Unique Access provides access to an extensive treatment protocol for Ataxia which utilises higher quantities of stem cells, innovative stem cell growth factors, extensive rehabilitation, and many supportive therapies and supplements. This effective combination of the most advanced medical technologies with functional medicine has helped patients achieve significant improvements.
Providing neuroprotection and possibly promoting regeneration are some of the reasons why stem cell therapies were recently studied as an option to treat neurodegenerative disorders.
In Ataxia, studies on animal models and humans also reported the therapeutic safety and efficacy of stem cell transplantation.
There are multi-lineage differentiation potentials and immuno-modulatory properties in Mesenchymal Stem Cells (MSCs), and they are theoretically good candidates for treating SCA. It has also been shown that, under appropriate conditions, UC-MSC can differentiate into neurons.
By stimulating resident stem cells, anti-apoptotic effects, antioxidant effects and release of neurotrophic factors, MSCs can possibly protect axons and promote neurogenesis.
Ataxia patients have experienced remarkable improvements such as:
- Increased mobility
Better balance and coordination
(improvements are visible in Berg Balance Scale (BBS))
- Improved fine and gross motor skills
- Improved speech and cognition
Overall, a better quality of life was seen in most GSC patients treated using a combination of human Umbilical Cord-Derived Mesenchymal Stem cells (UC-MSC) and rehabilitation.
Disease progression was also observed to be significantly slower in patients with progressive Ataxias.
We believe that there is always hope and that patients deserve access to effective and safe treatments. We are independent with an in-house medical department. We combine internationally accredited hospitals, next generation treatments, unique products and services that are integrative and effective to ensure best possible treatment results.
From her thoughts on her stem cell treatment to the members of the clinical staff, Pamela B discusses her stay at the hospital.
We make sure that the patient receives the correct and necessary stem cell type, quality, quantity and viability. Our exclusive research partner guarantees a stem cell viability of 95%, many injections have a staggering viability of 98-99%.
The treatment takes place in an internationally accredited tertiary care hospital and not in a hotel or clinic. This is important for the patient’s safety and care as the patient has access to all specialized departments & specialist doctors. This further increases the treatments efficiency.
Ataxia is characterised by an inability to maintain normal posture and stable movements. Rather than being an actual disease, it is a sign and symptom of a central nervous system abnormality. The underlying neurological abnormality, resulting to this condition, can be either acquired or hereditary. Ethanol poisoning, lithium poisoning, anti-epileptic drugs, brain tumours, stroke, and cerebelittis are among the common acquired causes.
Hereditary Ataxias are a group of neurodegenerative disorders characterised by degenerative atrophy of the cerebellum, brain stem and/or spinal cord. Spinocerebellar Ataxia (SCA) and Friedreich’s Ataxia (FRDA) are its most common forms. Genetic anticipation usually occurs in familial patients, with symptoms and signs getting more severe with each successive generation.
- Bastian AJ, Zackowski KM, Thach WT (May 2000).
“Cerebellar ataxia: torque deficiency or torque mismatch between joints?”. J. Neurophysiol. 83 (5): 3019–30. PMID 10805697.
- Forrest MD, Wall MJ, Press DA, Feng J (December 2012).
“The Sodium-Potassium Pump Controls the Intrinsic Firing of the Cerebellar Purkinje Neuron”. PLoS ONE. 7 (12): e51169. doi: 10.1371/journal.pone.0051169. PMC 3527461. PMID 23284664.
- Forrest MD (December 2014).
“The sodium-potassium pump is an information processing element in brain computation”. Frontiers in Physiology. 5 (472). doi: 10.3389/fphys.2014.00472.
- Calderon DP, Fremont R, Kraenzlin F, Khodakhah K (March 2011).
“The neural substrates of rapid-onset Dystonia-Parkinsonism”. Nature Neuroscience. 14 (3): 357–65. doi: 10.1038/nn.2753. PMC